New drug combo trial offers hope for lymphoma patients who stopped responding to standard treatments
NCT ID NCT06883526
Summary
This study is testing a new two-drug combination (ZG005 and gecacitinib) for people with lymphoma that has returned or hasn't responded to previous treatments. The first part aims to find a safe and effective dose, while the second part will measure how well the combination works to control the cancer. It will involve about 60 adult participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
Contact
Conditions
Explore the condition pages connected to this study.